Charles River Laboratories International Future Growth

Future criteria checks 1/6

Charles River Laboratories International se prevé un crecimiento anual de los beneficios y los ingresos de 11.2% y 5.3% respectivamente. Se prevé que el BPA sea de grow en 11.2% al año. Se prevé que la rentabilidad de los fondos propios sea de 13.9% en 3 años.

Key information

11.4%

Earnings growth rate

11.4%

EPS growth rate

Life Sciences earnings growth	20.9%
Revenue growth rate	5.3%
Future return on equity	13.9%
Analyst coverage	Good
Last updated	03 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:RV6 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4,887	629	648	990	8
12/31/2025	4,531	525	571	886	14
12/31/2024	4,220	420	455	753	14
12/30/2023	4,129	475	365	684	N/A
9/30/2023	4,216	475	368	698	N/A
7/1/2023	4,178	484	289	625	N/A
4/1/2023	4,092	496	275	626	N/A
12/31/2022	3,976	486	295	620	N/A
9/24/2022	3,781	436	280	614	N/A
6/25/2022	3,688	443	338	656	N/A
3/26/2022	3,630	422	412	693	N/A
12/25/2021	3,540	391	532	761	N/A
9/25/2021	3,426	397	452	670	N/A
6/26/2021	3,273	396	484	672	N/A
3/27/2021	3,041	375	479	648	N/A
12/26/2020	2,924	364	380	547	N/A
9/26/2020	2,824	301	446	589	N/A
6/27/2020	2,749	271	416	567	N/A
3/28/2020	2,724	248	385	535	N/A
12/28/2019	2,621	252	340	481	N/A
9/28/2019	2,532	231	295	440	N/A
6/29/2019	2,449	219	269	402	N/A
3/30/2019	2,377	227	264	393	N/A
12/29/2018	2,266	225	297	437	N/A
9/29/2018	2,143	135	321	421	N/A
6/30/2018	2,022	128	264	363	N/A
3/31/2018	1,906	129	248	342	N/A
12/30/2017	1,858	123	234	316	N/A
9/30/2017	1,846	198	N/A	310	N/A
7/1/2017	1,807	183	N/A	323	N/A
4/1/2017	1,772	164	N/A	303	N/A
12/31/2016	1,681	154	N/A	315	N/A
9/24/2016	1,568	143	N/A	299	N/A
6/25/2016	1,492	143	N/A	315	N/A
3/26/2016	1,398	156	N/A	321	N/A
12/26/2015	1,363	150	N/A	305	N/A
9/26/2015	1,339	146	N/A	284	N/A
6/27/2015	1,317	140	N/A	263	N/A
3/28/2015	1,319	127	N/A	234	N/A
12/27/2014	1,298	128	N/A	251	N/A
9/27/2014	1,257	120	N/A	214	N/A
6/28/2014	1,222	119	N/A	214	N/A
3/29/2014	1,174	111	N/A	205	N/A
12/28/2013	1,166	104	N/A	207	N/A
9/28/2013	1,156	108	N/A	210	N/A
6/29/2013	1,143	99	N/A	203	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: RV6(11.2% al año) es superior a la tasa de ahorro (0.6%).

Beneficios frente mercado: RV6Se prevé que los beneficios de la empresa (11.2% al año) crezcan menos que el mercado German (13% al año).

Beneficios de alto crecimiento: RV6Se prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: RV6(5.3% al año) se prevé que crezca más despacio que el mercado de German (5.4% al año).

Ingresos de alto crecimiento: RV6Se prevé que los ingresos de la empresa (5.3% al año) crezcan más despacio que 20% al año.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): RV6Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (15%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Charles River Laboratories International Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023

Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for the Year 2023 and Provides Revenue Guidance for the Year 2024

Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023

Charles River Laboratories International, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Charles River Laboratories International, Inc. Revises Revenue Guidance for 2022

Charles River Laboratories International, Inc. Revises Earnings Guidance for 2022

Recent updates

Charles River Laboratories International, Inc., Annual General Meeting, May 08, 2024

Insider recently sold €1.2m worth of stock

Insider recently sold €930k worth of stock

Charles River Laboratories International, Inc. (NYSE:CRL) acquired additional 41% stake in Noveprim Limited for approximately $210 million.

Full year 2023 earnings released: EPS: US$9.27 (vs US$9.57 in FY 2022)

Charles River Laboratories International, Inc. Introduces First Rapid Animal-Free Bacterial Endotoxin Test

Charles River Laboratories International, Inc. Appoints Reshema Kemps-Polanco to Board of Directors

Charles River Laboratories International, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

Now 21% undervalued

Charles River Laboratories International, Inc. Introduces Cliniprime Cryopreserved Leukopaks, Expanding Suite of Gmp-Compliant Cellular Products

Chairman recently bought €922k worth of stock

Third quarter 2023 earnings released: EPS: US$1.70 (vs US$1.90 in 3Q 2022)

Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Charles River Laboratories International, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Charles River Laboratories International, Inc. Unveils Lentivation Platform to Expedite Lvv-Based Gene Therapy Manufacturing

Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for the Year 2023 and Provides Revenue Guidance for the Year 2024

Insider recently sold €1.1m worth of stock

Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$1.89 (vs US$2.15 in 2Q 2022)

Now 20% undervalued

Now 21% undervalued

Glancy Prongay & Murray LLP Announces Investors with Substantial Losses Have Opportunity to Lead the Securities Fraud Class Action Lawsuit Against Charles River Laboratories International, Inc

Charles River Laboratories International, Inc. Launches Off-The-Shelf Lentiviral Vector Packaging Plasmids

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Charles River Laboratories International, Inc

Now 18% undervalued after recent price drop

Insider recently sold €170k worth of stock

First quarter 2023 earnings released: EPS: US$2.02 (vs US$1.84 in 1Q 2022)

Charles River Laboratories International, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Investor sentiment deteriorates as stock falls 16%

Independent Director recently bought €365k worth of stock

Full year 2022 earnings released: EPS: US$9.57 (vs US$7.77 in FY 2021)

Charles River Laboratories Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein

Charles River Laboratories International, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Charles River Laboratories International, Inc. (NYSE : CRL) acquired the remaining 80% stake in Samdi Tech, Inc. for $50 million.

Charles River Laboratories International, Inc. Announces the Launch of Their New CliniPrimeTM Suite of Good Manufacturing Practice Compliant Cellular Starting Materials

Charles River Establishes eXpDNA Plasmid Manufacturing Platform to Expedite DNA Programs

Arlington Management Employees, LLC acquired Avian Vaccine Business from Charles River Laboratories International, Inc. (NYSE:CRL).

Independent Director recently bought €313k worth of stock

Charles River Laboratories International, Inc. Appoints Craig B. Thompson to the Board

Charles River Laboratories International, Inc. Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection

Insider recently sold €117k worth of stock

Now 20% undervalued after recent price drop

An unknown buyer entered into a definitive agreement to acquire Avian Vaccine Business from Charles River Laboratories International, Inc. (NYSE:CRL) for approximately $200 million.

Charles River Laboratories International, Inc. Launches Hemacare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research

Charles River Laboratories International, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Charles River Launches Naavigation Vector Platform to Accelerate Gene Therapy Programs

Investor sentiment improved over the past week

Charles River Laboratories International, Inc. Receives Good Manufacturing Practice Certification from European Medicines Agency

Second quarter 2022 earnings released: EPS: US$2.15 (vs US$1.76 in 2Q 2021)

Charles River Laboratories International, Inc. Revises Revenue Guidance for 2022

Charles River Laboratories International, Inc. to Report Q2, 2022 Results on Aug 03, 2022

First quarter 2022 earnings released: EPS: US$1.84 (vs US$1.23 in 1Q 2021)

Charles River Laboratories International, Inc. Revises Earnings Guidance for 2022

Charles River Laboratories International, Inc. and Valo Health, Inc. Launch Logica, an Integrated Ai-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

Charles River Laboratories International, Inc. to Report Q1, 2022 Results on May 04, 2022

Charles River Laboratories International, Inc. (NYSE : CRL) acquired Explora BioLabs Holdings, Inc. for approximately $300 million.

Charles River Laboratories International, Inc. Announces Management Changes

Insider recently sold €102k worth of stock

Charles River Laboratories International, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year of 2022

Third quarter 2021 earnings released: EPS US$2.05 (vs US$2.07 in 3Q 2020)

Chairman recently sold €3.4m worth of stock

Charles River Laboratories International, Inc. Increases Earnings Guidance for the Year 2021

Second quarter 2021 earnings released: EPS US$1.76 (vs US$1.36 in 2Q 2020)

Charles River Laboratories International, Inc. (NYSE:CRL) completed the acquisition of Vigene Biosciences, Inc..

Charles River Laboratories International, Inc. (NYSE:CRL) signed an agreement to acquire Vigene Biosciences, Inc. for approximately $350 million from Signet Healthcare Partners and others.